Egalet Corporation (NASDAQ:EGLT) – Equities researchers at Gabelli issued their FY2021 EPS estimates for shares of Egalet Corporation in a research note issued on Tuesday. Gabelli analyst K. Kedra forecasts that the firm will post earnings of $0.65 per share for the year. Gabelli has a “Hold” rating on the stock.

Several other analysts have also recently weighed in on the company. JMP Securities reissued an “outperform” rating and set a $15.00 price target on shares of Egalet Corporation in a report on Wednesday. Zacks Investment Research upgraded Egalet Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, January 4th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Egalet Corporation in a research note on Monday, December 19th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $12.60.

TRADEMARK VIOLATION WARNING: “Egalet Corporation Expected to Post FY2021 Earnings of $0.65 Per Share (EGLT)” was published by Watch List News and is the propert of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this piece can be viewed at http://www.watchlistnews.com/egalet-corporation-expected-to-post-fy2021-earnings-of-0-65-per-share-eglt/1060667.html.

Shares of Egalet Corporation (NASDAQ:EGLT) traded down 2.96% during mid-day trading on Wednesday, hitting $5.90. The stock had a trading volume of 657,480 shares. Egalet Corporation has a 52 week low of $4.34 and a 52 week high of $10.00. The firm’s market cap is $145.22 million. The stock has a 50 day moving average price of $7.86 and a 200 day moving average price of $7.13.

Egalet Corporation (NASDAQ:EGLT) last announced its earnings results on Friday, November 4th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.90) by $0.20. The business had revenue of $4.70 million for the quarter, compared to the consensus estimate of $4.50 million. Egalet Corporation had a negative return on equity of 127.84% and a negative net margin of 251.79%. The business’s revenue was up 176.5% compared to the same quarter last year.

Large investors have recently modified their holdings of the company. ProShare Advisors LLC raised its stake in shares of Egalet Corporation by 16.2% in the second quarter. ProShare Advisors LLC now owns 21,386 shares of the specialty pharmaceutical company’s stock worth $106,000 after buying an additional 2,977 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Egalet Corporation during the second quarter worth $125,000. Credit Suisse AG raised its stake in shares of Egalet Corporation by 15.6% in the third quarter. Credit Suisse AG now owns 16,815 shares of the specialty pharmaceutical company’s stock worth $127,000 after buying an additional 2,270 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in shares of Egalet Corporation during the second quarter worth $177,000. Finally, Teachers Advisors Inc. purchased a new stake in shares of Egalet Corporation during the second quarter worth $180,000. Institutional investors and hedge funds own 70.62% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Egalet Corporation Expected to Post FY2021 Earnings of $0.65 Per Share (EGLT)” was published by Watch List News and is the propert of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this piece can be viewed at http://www.watchlistnews.com/egalet-corporation-expected-to-post-fy2021-earnings-of-0-65-per-share-eglt/1060667.html.

In related news, CFO Stan Musial sold 13,480 shares of the business’s stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $7.73, for a total transaction of $104,200.40. Following the sale, the chief financial officer now owns 54,500 shares in the company, valued at approximately $421,285. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Mark Strobeck sold 8,700 shares of the business’s stock in a transaction on Friday, December 30th. The stock was sold at an average price of $7.81, for a total value of $67,947.00. Following the sale, the chief operating officer now owns 38,180 shares in the company, valued at approximately $298,185.80. The disclosure for this sale can be found here. Corporate insiders own 13.20% of the company’s stock.

Egalet Corporation Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

5 Day Chart for NASDAQ:EGLT

Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.